English
 
Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Photodynamic Opening of the Blood–Brain Barrier and the Meningeal Lymphatic System: The New Niche in Immunotherapy for Brain Tumors

Authors

Semyachkina-Glushkovskaya,  Oxana
External Organizations;

Terskov,  Andrey
External Organizations;

Khorovodov,  Alexander
External Organizations;

Telnova,  Valeria
External Organizations;

Blokhina,  Inna
External Organizations;

Saranceva,  Elena
External Organizations;

/persons/resource/Juergen.Kurths

Kurths,  Jürgen
Potsdam Institute for Climate Impact Research;

External Ressource
No external resources are shared
Fulltext (public)
Supplementary Material (public)
There is no public supplementary material available
Citation

Semyachkina-Glushkovskaya, O., Terskov, A., Khorovodov, A., Telnova, V., Blokhina, I., Saranceva, E., Kurths, J. (2022): Photodynamic Opening of the Blood–Brain Barrier and the Meningeal Lymphatic System: The New Niche in Immunotherapy for Brain Tumors. - Pharmaceutics, 14, 12, 2612.
https://doi.org/10.3390/pharmaceutics14122612


Cite as: https://publications.pik-potsdam.de/pubman/item/item_27962
Abstract
Photodynamic therapy (PDT) is a promising add-on therapy to the current standard of care for patients with glioblastoma (GBM). The traditional explanation of the anti-cancer PDT effects involves the PDT-induced generation of a singlet oxygen in the GBM cells, which causes tumor cell death and microvasculature collapse. Recently, new vascular mechanisms of PDT associated with opening of the blood–brain barrier (OBBB) and the activation of functions of the meningeal lymphatic vessels have been discovered. In this review, we highlight the emerging trends and future promises of immunotherapy for brain tumors and discuss PDT-OBBB as a new niche and an important informative platform for the development of innovative pharmacological strategies for the modulation of brain tumor immunity and the improvement of immunotherapy for GBM.